Summary
32 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 7.0 years of operating profit.
- Revenue growth is slowing: 3.0% a year over the last 3 years against 25% over 5 years.
- It missed profit estimates 6 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 25% a year over 5 years. Over the last 3 years it grew by 3.0% a year. For the next fiscal year analysts expect revenue to fall by 11%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $228.2M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 21.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 2
- Sell 1
Today's price within the analysts' price targets
The average target of $9.83 is 63% above today's price. 75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Respiratory Health 100%
By region
The company reports no revenue by region.
Respiratory Health brings in 100% of revenue.
Segments in detail